Overview
VKTX market data
Price History
VKTX price chart · 1M
- O
- 26.50
- H
- 26.87
- L
- 25.29
- C
- 25.48
- Vol
- 195,319.00
Daily history from Jan 4, 2016
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $26.50
- Previous Close
- $26.67
- Day High
- $26.87
- Day Low
- $25.29
- 52 Week High
- $43.08
- 52 Week Low
- $25.29
- 7 Day Return
- -10.72%
- 30 Day Return
- -19.12%
- 90 Day Return
- -29.99%
- 1 Year Return
- -22.89%
- Daily Notional Volume
- $5M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.19 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.67 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $25.77 – $43.15 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.3B · P/B 6.22.
Company News
10 captured
4 High-Risk Stocks Built for Big ReturnsThe Motley Fool ·
Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call.The Motley Fool ·
Prediction: This Stock Could Double Over the Next 5 YearsThe Motley Fool ·
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why.The Motley Fool ·
Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?The Motley Fool ·